Cannabigerol
Chemical compound
Nº Q412122 ★
Comum · Saberes
Cannabigerol
Chemical compound
Cannabigerol (CBG) is a cannabinoid and minor constituent of cannabis. It is one of more than 120 identified cannabinoids found in the plant genus Cannabis. The compound is the decarboxylated form of cannabigerolic acid (CBGA), the parent molecule from which other cannabinoids are biosynthesized.
Último preço
—
Preço mínimo
—
Mediana 7 d
—
Vendas 30 d
0
Faixa 30 d
—
Em circulação
0
Cotação
mediana
mín – máx
vendas
Sem vendas no período
Ver tabela
| Data | mediana | Mín | Máx | vendas |
|---|
Histórico de vendas
- Última venda
- —
- Média 30 d
- —
- Mínima 30 d
- —
- Máxima 30 d
- —
- Vendas 7 d
- 0
- Vendas 30 d
- 0
Ainda sem vendas.
Vendas anônimas: sem comprador nem vendedor. Os números contam só vendas entre jogadores.
Na Wikipédia
Texto em inglês Ainda não há artigo no seu idioma: trecho em inglês.
Cannabigerol (CBG) is a cannabinoid and minor constituent of cannabis. It is one of more than 120 identified cannabinoids found in the plant genus Cannabis. The compound is the decarboxylated form of cannabigerolic acid (CBGA), the parent molecule from which other cannabinoids are biosynthesized. That's why it is known as the mother of all cannabinoids. During plant growth, most of the CBG is converted into other cannabinoids, primarily tetrahydrocannabinol (THC) or cannabidiol (CBD), leaving about 1% CBG in finished plant material. Some strains, however, produce larger amounts of CBG and CBGA, while having low quantities of other cannabinoids, such as THC and CBD. The pharmacodynamics of CBG are complex. It is a relatively weak ligand of the cannabinoid receptors, where it acts as a weak partial agonist. Conversely, it is a much more potent agonist of the α2-adrenergic receptor, antagonist of the serotonin 5-HT1A receptor, and antagonist of the transient receptor potential channel TRPM8. CBG also has a variety of other actions that may additionally contribute to its effects. CBG is sold as a dietary supplement. Safety concerns have been raised by the FDA due to the potent activation of α2-adrenergic receptors by CBG, which may produce sedation and potentially undesirable cardiovascular effects such as decreased heart rate and blood pressure.
Texto: Wikipédia em inglês, CC BY-SA 4.0. · Imagem: Jynto (more from this user) (CC0) ·